Prevention of Persistence of Bacterial Vaginosis

Prevention of Persistence of Bacterial Vaginosis: The Effects of High Dose Intravaginal Metronidazole

This purpose of this study will be to conduct a double-blind, randomized, controlled clinical trial to determine the association between intravaginal high dose metronidazole (750mg), intravaginal high dose metronidazole combined with an antifungal agent(750mg metronidazole + 200mg miconazole) and low dose (37.5mg) intravaginal metronidazole, with the rate of persistent bacterial vaginosis.

Inclusion Criteria:

• women 18-40 yrs old
• abnormal vaginal discharge or malodor
• positive QuickVue test
• positive KOH whiff test
• Positive finding of clue cells greater than or equal to 20% on wet mount
• Able to give informed consent
• willing to abstain from alcohol during the 5 day therapy and 1 day following

Exclusion Criteria:

• immunocompromised women
• symptomatic VVC
• pregnancy or positive pregnancy test
• menstruating or breastfeeding women
• other oral or vaginal antifungal or antimicrobial drugs w/in past 2 wks
• women with MPC, PID